What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · SHORT · AZN

AstraZeneca's heart drug flops in trials — short the failed-drug fallout

AstraZeneca's stock just took a dive because an experimental heart disease drug failed its clinical trial. When drug trials fail, the company loses out on a future revenue stream, causing a sudden sell-off.

Idea

When a major drug trial fails, it often triggers a panic sell-off as investors rush to the exits. This selling pressure can cause the stock to fall sharply in a short period as the market re-evaluates the company's future earnings potential without that drug. Since big institutions often dump shares on bad news to manage risk, the downward pressure can linger for several days as the dust settles.

Key details

AZND1#biotech#mean-reversion#short-bias

Community

Upvotes

Views

Copies

Cosigns

News sources

AstraZeneca Plunges After New Heart Disease Drug Fails Trial — Yahoo Finance

Related ideas

Chip stocks priced for perfection, Morgan Stanley waves red flag — fade the rally
Traders betting on a July rate hike — short the broad market ahead of inflation data
Vertex drops $10B to dominate hormone treatments — ride the acquisition momentum

AZN trade ideas
Latest market news